Healthcare / Drug Manufacturers - Specialty & GenericNSE
$380.80
-2.10 (-0.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $802.2M · quality 50.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$34.8B
P/E
17.8x
↓EV/EBITDA
13.0x
↑ROE
12.6%
↑Gross Margin
36.9%
↓Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
-1.8%
FCF CAGR
—
FCF margin
3.1%
FCF / Net income
0.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $25.65B · net income $1.95B · FCF $802.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $25.65B | $25.65B | $23.87B | $25.09B | $27.06B |
| Net Income | $1.95B | $1.95B | $1.68B | $1.71B | $1.66B |
| EBITDA | $3.12B | $3.12B | $3.03B | $3.20B | $3.08B |
| EPS | — | — | 18.35 | 18.56 | 17.97 |
| Gross Margin | 36.9% | 36.9% | 35.4% | 33.9% | 17.9% |
| Operating Margin | 9.4% | 9.4% | 9.7% | 11.1% | 9.8% |
| Net Margin | 7.6% | 7.6% | 7.0% | 6.8% | 6.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.37 | 0.37 | 0.45 | 0.44 | 0.51 |
| Current Ratio | 1.59 | 1.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $802.2M | $802.2M | $674.2M | $1.33B | $-315.0M |
| Returns | |||||
| ROE | 12.6% | 12.6% | 12.3% | 13.4% | 13.9% |
| Valuation | |||||
| P/E | 17.82 | 17.82 | 18.14 | 26.54 | 21.58 |
| EV/EBITDA | 12.98 | 12.98 | 12.03 | 15.87 | 13.62 |
| P/B | 2.24 | 2.24 | 2.22 | 3.53 | 3.01 |
| Growth & Yield | |||||
| Revenue Growth | 7.5% | 7.5% | -4.9% | -7.3% | — |
| EPS Growth | — | — | -1.1% | 3.3% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.0%
Start / end P/E
n/dx → n/dx
EPS bridge
18.35 → n/d
Residual
-19.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.